AR096878A1 - FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO PARA ADMINISTRAR POR INHALACIÓN - Google Patents
FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO PARA ADMINISTRAR POR INHALACIÓNInfo
- Publication number
- AR096878A1 AR096878A1 ARP140102562A ARP140102562A AR096878A1 AR 096878 A1 AR096878 A1 AR 096878A1 AR P140102562 A ARP140102562 A AR P140102562A AR P140102562 A ARP140102562 A AR P140102562A AR 096878 A1 AR096878 A1 AR 096878A1
- Authority
- AR
- Argentina
- Prior art keywords
- particles
- dry powder
- corticosteroid
- inhalation
- anticholinergic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Formulaciones en polvo seco para inhalación que comprenden una combinación de un anticolinérgico, un agonista de adrenoceptor b2 de acción prolongada y un corticosteroide; proceso de preparación y usos terapéuticos de las mismas. Reivindicación 1: Una formulación en polvo seco para usar en un inhalador en polvo seco (DPI), caracterizada porque comprende: a) una fracción de partículas finas que consiste en una mezcla, que se prepara por comezclado en un aparato de alta energía durante un periodo de menos de 20 minutos, entre 90 y 99,5 por ciento en peso de partículas micronizadas de un excipiente fisiológicamente aceptable y entre 0,5 y 10 por ciento en peso de estearato de magnesio, en donde al menos el 90% de todas dichas partículas tiene un diámetro de volumen menor que 15 mm, preferentemente menor que 12 mm, y el diámetro mediano de volumen de dichas partículas está comprendido entre 3 y 7 mm, preferentemente entre 4 y 6 mm; b) una fracción de partículas gruesas que consiste en un excipiente fisiológicamente aceptable que tiene un diámetro mediano de masa igual o mayor que 100 mm, en donde la proporción entre las partículas finas y las partículas gruesas es entre 1:99 y 30:70 por ciento en peso; y c) partículas micronizadas de un anticolinérgico, un corticosteroide para inhalación (ICS), y un agonista b2 de acción prolongada (LABA) como principios activos. Reivindicación 3: La formulación en polvo de acuerdo a la reivindicación 1 ó 2, caracterizada porque el LABA es formoterol fumarato dihidratado, el ICS es dipropionato de beclometasona y el anticolinérgico es bromuro de glicopirronio.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13176114 | 2013-07-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096878A1 true AR096878A1 (es) | 2016-02-03 |
Family
ID=48793010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140102562A AR096878A1 (es) | 2013-07-11 | 2014-07-10 | FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO PARA ADMINISTRAR POR INHALACIÓN |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR096878A1 (es) |
| MA (1) | MA38782B1 (es) |
-
2014
- 2014-07-10 AR ARP140102562A patent/AR096878A1/es not_active Application Discontinuation
-
2016
- 2016-01-08 MA MA38782A patent/MA38782B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA38782A1 (fr) | 2016-04-29 |
| MA38782B1 (fr) | 2016-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20212110A1 (es) | Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacion | |
| PE20141703A1 (es) | Formulacion seca en polvo que comprende un corticoesteroide y un beta-adrenergico para administrar por inhalacion | |
| PE20160155A1 (es) | Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos | |
| AR070834A1 (es) | Dosificacion y formulacion de aclidinio para el tratamiento de trastornos respiratorios | |
| WO2008084312A3 (en) | Micronised particles of low-dosage strength active agents for powder formulations for inhalation | |
| AR075516A1 (es) | Composicion farmaceutica para inhalacion | |
| FI3500241T3 (fi) | Yhdistelmähoito copd:lle | |
| RU2014140539A (ru) | Агрегированные частицы | |
| JP2013542940A5 (es) | ||
| PE20141036A1 (es) | Nueva dosificacion y formulacion | |
| MY175781A (en) | Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation | |
| PE20030948A1 (es) | Proceso para la preparacion de una suspension esteril de particulas de dipropionato de beclometasona para administracion por inhalacion | |
| PH12014502662A1 (en) | Novel dosage form and formulation of abediterol | |
| AR091161A1 (es) | Composicion farmaceutica para inhalacion, metodo, uso | |
| JP2015519356A5 (es) | ||
| CL2023000998A1 (es) | Formulación farmacéutica para inhalador presurizado de dosis medidas | |
| BR112015027247A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores contendo as mesmas | |
| RU2013157398A (ru) | Композиция | |
| JP2014520874A5 (es) | ||
| MY191712A (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
| AR096878A1 (es) | FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO PARA ADMINISTRAR POR INHALACIÓN | |
| MX2016014256A (es) | Formulaciones y metodos para el suministro vaginal de antiprogestinas. | |
| EA201591871A1 (ru) | Фармацевтическая композиция, содержащая будесонид и формотерол | |
| AR086248A1 (es) | Formulacion en forma de suspension mejorada de un corticosteroide que puede administrarse por inhalacion | |
| MX2019012930A (es) | Proceso para preparacion de una formulacion de polvo seco que incluye un anticolinergico, un corticosteroide y un beta-adrenergico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |